



**Press release**

Malmö, Sweden, March 10, 2022

## **Acarix presents at the Redeye Artificial Intelligence Seminar 2022.**

**On March 16 at 1.50pm, Helen Ljungdahl Round, CEO, Acarix AB and Samuel Schmidt, Ass. Professor and CADScor®System inventor will present on the AI-based CADScor®System, a rapid assessment of coronary artery disease.**

The session will be live broadcast on this link:

<https://us02web.zoom.us/j/86991641341?pwd=WGx2V0c1aXkvbVhBQTdhdWhESGZiUT09>.

The recording and the presentations will also be available after the event.

**For more information contact:**

Philip Siberg, Chairman of the Board, phone +46 70 7906734, [philip.siberg@acarix.com](mailto:philip.siberg@acarix.com)

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, [helen.round@acarix.com](mailto:helen.round@acarix.com)

*The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire.*

**About Acarix:**

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes and can help rule out more than one third of patients with at least 96% certainty (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)) is Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com).